Clinical trials: TACE
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma
The current standard treatment for intermediate-stage HCC (BCLC stage B) is transcatheter arterial chemoembolization (TACE) alone. The combination of TACE with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA
- Trial name
- TORCH (NCT02435953)
- Testing
- TACE, RFA
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Ming Zhao
Hepatocellular Carcinoma
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare…
- Trial name
- LOST-B (NCT05537402)
- Testing
- Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ATTACH (NCT07239245)
- Testing
- Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE)
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
- Trial name
- BRISK TA (NCT00908752)
- Testing
- Brivanib, TACE Therapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 734 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
DEB-TACE Treatment in 367 Liver Cancer Patients
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral…
- Trial name
- NCT03317483
- Volunteers
- 367 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
M-TACE Treatment for Unresectable Hepatocellular Carcinoma
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).
- Trial name
- NCT05875558
- Testing
- M-TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC
Hepatocellular carcinoma is a highly malignant tumor that is progressing rapidly. Hepatic arterial embolization chemotherapy (TACE) is a common method for the treatment of unresectable of hepatocellular carcinoma.But for patients…
- Trial name
- NCT03243916
- Testing
- TACE plus Cyber knife
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma
Drug-eluting Bead in Hepatocellular Carcinoma
In unresectable hepatocellular carcinoma, TACE using Lipiodol/anti cancer agent emulsion is the standard treatment and reported as a significantly better treatment through randomized comparison study like Llovet, etc.
- Trial name
- REDEBUT (NCT01332669)
- Testing
- DebDox TACE
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Liver Metastases, Colorectal Cancer
Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options.
- Trial name
- SECAIII (NCT03494946)
- Testing
- Liver transplantation, Chemotherapy
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular…
- Trial name
- NCT03084380
- Testing
- Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Hepatocellular Carcinoma
TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
The primary objective of this phase I dose escalation study is to determine the maximum tolerated dose of TH-302 when administered with doxorubicin via trans-arterial chemo-embolization (TACE) in patients with hepatocellular…
- Trial name
- NCT01721941
- Testing
- Phase I Dose level -1, Phase I dose level 1, Phase I Dose level 2
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Clinic Cancer Center
Hepatocellular Carcinoma
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
This study used (cTACE or DEB-TACE + FOLFOX scheme HAIC) combined with PD-1 antibody camrelizumab and apatinib mesylas in the treatment of patients with advanced liver cancer, to evaluate the effectiveness and safety of the…
- Trial name
- NCT04479527
- Testing
- Camrelizumab
- Volunteers
- 34 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
- Conditions
- Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma, Digestive System Neoplasms
- Trial name
- NCT06794073
- Testing
- Multimodal Thermal Therapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC)…
- Trial name
- NCT03791918
- Testing
- Lenvatinib, PD-1 antibody, TACE
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Adjuvant
Adjuvant TACE in HCC With High-risk Recurrence Factors
The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended…
- Conditions
- Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
- Trial name
- NCT07417397
- Testing
- Adjuvant transarterial chemoembolization, Intensive follow-up
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma (HCC)
A Study of DC-CIK to Treat Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).
- Trial name
- NCT01821482
- Testing
- Dendritic and Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma, Portal Hypertension
Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)
The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.
- Trial name
- NCT05703750
- Testing
- TACE ± Systemic therapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Zhongda Hospital
Advanced Unresectable Hepatocellular Carcinoma
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
This clinical study aims to evaluate the efficacy and safety of Retlirafusp alfa Injection (SHR-1701) combined with apatinib in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after…
- Trial name
- NCT07749859
- Testing
- Retlirafusp alfa Injection, apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences